{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:36:21Z","timestamp":1789788981003,"version":"4.0.1"},"reference-count":139,"publisher":"Cold Spring Harbor Laboratory","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cold Spring Harb Perspect Med"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1101\/cshperspect.a024430","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T03:54:30Z","timestamp":1478922870000},"page":"a024430","source":"Crossref","is-referenced-by-count":42,"title":["Insights from Therapeutic Studies for PrP Prion Disease"],"prefix":"10.1101","volume":"7","author":[{"given":"Kenta","family":"Teruya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Doh-ura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"246","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"2018091410343384000_7.3.a024430.1","doi-asserted-by":"crossref","first-page":"e1002651","DOI":"10.1371\/journal.ppat.1002651","article-title":"Five questions on prion diseases","volume":"8","year":"2012","journal-title":"PLoS Pathog"},{"key":"2018091410343384000_7.3.a024430.2","doi-asserted-by":"crossref","first-page":"e1005073","DOI":"10.1371\/journal.ppat.1005073","article-title":"Double-edge sword of sustained ROCK activation in prion diseases through neuritogenesis defects and prion accumulation","volume":"11","year":"2015","journal-title":"PLos Pathog"},{"key":"2018091410343384000_7.3.a024430.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature14510"},{"key":"2018091410343384000_7.3.a024430.4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2294"},{"key":"2018091410343384000_7.3.a024430.5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.str.2013.11.009","article-title":"Structural basis of prion inhibition by phenothiazine compounds","volume":"22","year":"2014","journal-title":"Structure"},{"key":"2018091410343384000_7.3.a024430.6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.15.8462-8469.2003"},{"key":"2018091410343384000_7.3.a024430.7","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000134853.36429.0e"},{"key":"2018091410343384000_7.3.a024430.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317164110"},{"key":"2018091410343384000_7.3.a024430.9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0035-3787(05)85062-3","article-title":"Hereditary Creutzfeldt\u2013Jakob disease caused by a mutation at codon 200","volume":"161","year":"2005","journal-title":"Rev Neurol (Paris)"},{"key":"2018091410343384000_7.3.a024430.10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7785-7791.2005"},{"key":"2018091410343384000_7.3.a024430.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322377111"},{"key":"2018091410343384000_7.3.a024430.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.10.5468"},{"key":"2018091410343384000_7.3.a024430.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02108.x"},{"key":"2018091410343384000_7.3.a024430.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5781.212"},{"key":"2018091410343384000_7.3.a024430.15","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90360-3"},{"key":"2018091410343384000_7.3.a024430.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1992.tb09437.x"},{"key":"2018091410343384000_7.3.a024430.17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/JVI.67.2.643-650.1993","article-title":"Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells","volume":"67","year":"1993","journal-title":"J Virol"},{"key":"2018091410343384000_7.3.a024430.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110837"},{"key":"2018091410343384000_7.3.a024430.19","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93128-V"},{"key":"2018091410343384000_7.3.a024430.20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(05)64378-4","article-title":"Prion protein gene analysis in new variant cases of Creutzfeldt\u2013Jakob disease","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"2018091410343384000_7.3.a024430.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70049-3"},{"key":"2018091410343384000_7.3.a024430.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10336"},{"key":"2018091410343384000_7.3.a024430.23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12035-014-8709-6","article-title":"Characteristic CSF prion seeding efficiency in humans with prion diseases","volume":"51","year":"2015","journal-title":"Mol Neurobiol"},{"key":"2018091410343384000_7.3.a024430.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02866081","article-title":"\u00dcber eine eigenartige herdf\u00f6rmige erkrankung des zentralnervensystems (Vorl\u00e4ufige mitteilung) [About a rare focal disease of the central nervous system (preliminary communication)]","volume":"57","year":"1920","journal-title":"Z ges Neurol Psychiatr"},{"key":"2018091410343384000_7.3.a024430.25","first-page":"512","article-title":"Unsuccessful treatment of Creutzfeldt\u2013Jakob disease with acyclovir","volume":"1","year":"1984","journal-title":"Lancet"},{"key":"2018091410343384000_7.3.a024430.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001888"},{"key":"2018091410343384000_7.3.a024430.27","first-page":"194","article-title":"Psychiatric manifestations of a new variant of Creutzfeldt\u2013Jakob disease. Apropos of a case","volume":"27","year":"2001","journal-title":"Encephale"},{"key":"2018091410343384000_7.3.a024430.28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.10.4894-4897.2000"},{"key":"2018091410343384000_7.3.a024430.29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.10.4999-5006.2004"},{"key":"2018091410343384000_7.3.a024430.30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00917-06"},{"key":"2018091410343384000_7.3.a024430.31","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-006-9122-0"},{"key":"2018091410343384000_7.3.a024430.32","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-67-3-463"},{"key":"2018091410343384000_7.3.a024430.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162195499"},{"key":"2018091410343384000_7.3.a024430.34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/19336896.2015.1027857","article-title":"Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases","volume":"9","year":"2015","journal-title":"Prion"},{"key":"2018091410343384000_7.3.a024430.35","first-page":"564","article-title":"Repeated suppression of Creutzfeldt\u2013Jakob disease with vidarabine","volume":"2","year":"1982","journal-title":"Lancet"},{"key":"2018091410343384000_7.3.a024430.36","doi-asserted-by":"publisher","DOI":"10.1021\/jm101250y"},{"key":"2018091410343384000_7.3.a024430.37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a9f3b4"},{"key":"2018091410343384000_7.3.a024430.38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000673"},{"key":"2018091410343384000_7.3.a024430.39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02145-09"},{"key":"2018091410343384000_7.3.a024430.40","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1021\/jm5001425","article-title":"Successes and challenges in phenotype-based lead discovery for prion diseases","volume":"57","year":"2014","journal-title":"J Med Chem"},{"key":"2018091410343384000_7.3.a024430.41","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148596.15681.4D"},{"key":"2018091410343384000_7.3.a024430.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70307-7"},{"key":"2018091410343384000_7.3.a024430.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.01.030"},{"key":"2018091410343384000_7.3.a024430.44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.virol.2015.09.002","article-title":"Structure-activity analysis and antiprion mechanism of isoprenoid compounds","volume":"486","year":"2015","journal-title":"Virology"},{"key":"2018091410343384000_7.3.a024430.45","first-page":"87","article-title":"Autophagy, prion infection and their mutual interactions","volume":"12","year":"2010","journal-title":"Curr Issues Mol Biol"},{"key":"2018091410343384000_7.3.a024430.46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1532-5415.1973.tb01676.x","article-title":"Antiviral drugs in Jakob\u2013Creutzfeldt disease","volume":"21","year":"1973","journal-title":"J Am Geriatr Soc"},{"key":"2018091410343384000_7.3.a024430.47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1440-1789.2011.01245.x","article-title":"Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion","volume":"32","year":"2012","journal-title":"Neuropathol"},{"key":"2018091410343384000_7.3.a024430.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.03.037"},{"key":"2018091410343384000_7.3.a024430.49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000069083","article-title":"Levetiracetam control of myoclonus in a patient with Creutzfeldt\u2013Jakob disease","volume":"49","year":"2003","journal-title":"Eur Neurol"},{"key":"2018091410343384000_7.3.a024430.50","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.19754-0"},{"key":"2018091410343384000_7.3.a024430.51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.04035.x"},{"key":"2018091410343384000_7.3.a024430.52","doi-asserted-by":"publisher","DOI":"10.1007\/BF02870932"},{"key":"2018091410343384000_7.3.a024430.53","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000106954.54011.80"},{"key":"2018091410343384000_7.3.a024430.54","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2180"},{"key":"2018091410343384000_7.3.a024430.55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303510110"},{"key":"2018091410343384000_7.3.a024430.56","unstructured":"Kawagoe K , Motoki K , Odagiri T , Suzuki N , Chen C-J , Mimura T . 2004. Hydrazone derivative. WIPO Publication No. WO\/2004\/087641. October 14."},{"key":"2018091410343384000_7.3.a024430.57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01563-07"},{"key":"2018091410343384000_7.3.a024430.58","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.29.927"},{"key":"2018091410343384000_7.3.a024430.59","first-page":"403","article-title":"Quinacrine administration to a patient with Creutzfeldt\u2013Jakob disease who received a cadaveric dura mater graft\u2014An EEG evaluation","volume":"43","year":"2003","journal-title":"Rinsho Shinkeigaku"},{"key":"2018091410343384000_7.3.a024430.60","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1447-7"},{"key":"2018091410343384000_7.3.a024430.61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.2.1044-1046.2006"},{"key":"2018091410343384000_7.3.a024430.62","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00715-06"},{"key":"2018091410343384000_7.3.a024430.63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.161274798"},{"key":"2018091410343384000_7.3.a024430.64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6218.902-a"},{"key":"2018091410343384000_7.3.a024430.65","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113136660171"},{"key":"2018091410343384000_7.3.a024430.66","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cmdc.201300007","article-title":"2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease","volume":"8","year":"2013","journal-title":"Chem Med Chem"},{"key":"2018091410343384000_7.3.a024430.67","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.205799"},{"key":"2018091410343384000_7.3.a024430.68","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/21.3.202"},{"key":"2018091410343384000_7.3.a024430.69","doi-asserted-by":"publisher","DOI":"10.1126\/science.1090187"},{"key":"2018091410343384000_7.3.a024430.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.surneu.2005.03.035"},{"key":"2018091410343384000_7.3.a024430.71","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.114801"},{"key":"2018091410343384000_7.3.a024430.72","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1056\/NEJMe1407419","article-title":"Shaken, not sonicated?","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"2018091410343384000_7.3.a024430.73","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181cd7374"},{"key":"2018091410343384000_7.3.a024430.74","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23589"},{"key":"2018091410343384000_7.3.a024430.75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809716"},{"key":"2018091410343384000_7.3.a024430.76","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2174\/15680266113136660168","article-title":"Strain specificity and drug resistance in anti-prion therapy","volume":"13","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"2018091410343384000_7.3.a024430.77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404401"},{"key":"2018091410343384000_7.3.a024430.78","doi-asserted-by":"publisher","DOI":"10.1038\/nature11058"},{"key":"2018091410343384000_7.3.a024430.79","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1925"},{"key":"2018091410343384000_7.3.a024430.80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001138"},{"key":"2018091410343384000_7.3.a024430.81","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.3.1281-1288.2004"},{"key":"2018091410343384000_7.3.a024430.82","doi-asserted-by":"publisher","DOI":"10.2174\/1389200003339270"},{"key":"2018091410343384000_7.3.a024430.83","doi-asserted-by":"publisher","DOI":"10.4161\/auto.25381"},{"key":"2018091410343384000_7.3.a024430.84","doi-asserted-by":"publisher","DOI":"10.1159\/000076350"},{"key":"2018091410343384000_7.3.a024430.85","first-page":"47","article-title":"Amantadine in Creutzfeldt\u2013Jakob disease. Review of the literature and case contribution","volume":"30","year":"1984","journal-title":"Riv Neurobiol"},{"key":"2018091410343384000_7.3.a024430.86","first-page":"793","article-title":"Acyclovir in Creutzfeldt\u2013Jakob disease","volume":"1","year":"1984","journal-title":"Lancet"},{"key":"2018091410343384000_7.3.a024430.87","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305590"},{"key":"2018091410343384000_7.3.a024430.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.05.060"},{"key":"2018091410343384000_7.3.a024430.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2011.04.016"},{"key":"2018091410343384000_7.3.a024430.90","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03775-13"},{"key":"2018091410343384000_7.3.a024430.91","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5809.349-b"},{"key":"2018091410343384000_7.3.a024430.92","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq216"},{"key":"2018091410343384000_7.3.a024430.93","doi-asserted-by":"publisher","DOI":"10.1007\/128_2011_184"},{"key":"2018091410343384000_7.3.a024430.94","doi-asserted-by":"publisher","DOI":"10.4161\/pri.19430"},{"key":"2018091410343384000_7.3.a024430.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315200"},{"key":"2018091410343384000_7.3.a024430.96","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02451-14"},{"key":"2018091410343384000_7.3.a024430.97","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000113764.35026.EF"},{"key":"2018091410343384000_7.3.a024430.98","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W"},{"key":"2018091410343384000_7.3.a024430.99","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.104505"},{"key":"2018091410343384000_7.3.a024430.100","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6559"},{"key":"2018091410343384000_7.3.a024430.101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29236"},{"key":"2018091410343384000_7.3.a024430.102","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3302"},{"key":"2018091410343384000_7.3.a024430.103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712173172505"},{"key":"2018091410343384000_7.3.a024430.104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.23.13363"},{"key":"2018091410343384000_7.3.a024430.105","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70063-7"},{"key":"2018091410343384000_7.3.a024430.106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2710.2010.01233.x","article-title":"The evolving understanding of the analgesic mechanism of action of flupirtine","volume":"37","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2018091410343384000_7.3.a024430.107","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.7.5.713"},{"key":"2018091410343384000_7.3.a024430.108","first-page":"18","article-title":"Creutzfeldt\u2013Jakob disease with focal onset unsuccessfully treated with amantadine","volume":"40","year":"1975","journal-title":"Bull Los Angeles Neurol Soc"},{"key":"2018091410343384000_7.3.a024430.109","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.258"},{"key":"2018091410343384000_7.3.a024430.110","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(03)00342-5"},{"key":"2018091410343384000_7.3.a024430.111","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5347"},{"key":"2018091410343384000_7.3.a024430.112","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.36.4.581"},{"key":"2018091410343384000_7.3.a024430.113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054915"},{"key":"2018091410343384000_7.3.a024430.114","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-004-6926-7"},{"key":"2018091410343384000_7.3.a024430.115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ana.10530","article-title":"Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt\u2013Jakob disease","volume":"53","year":"2003","journal-title":"Ann Neurol"},{"key":"2018091410343384000_7.3.a024430.116","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410430618"},{"key":"2018091410343384000_7.3.a024430.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2013.12.019"},{"key":"2018091410343384000_7.3.a024430.118","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0912-4"},{"key":"2018091410343384000_7.3.a024430.119","doi-asserted-by":"publisher","DOI":"10.2174\/1871526510909010081"},{"key":"2018091410343384000_7.3.a024430.120","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83578-0"},{"key":"2018091410343384000_7.3.a024430.121","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000308955.25760.c2"},{"key":"2018091410343384000_7.3.a024430.122","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5315.1119"},{"key":"2018091410343384000_7.3.a024430.123","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2000.3840"},{"key":"2018091410343384000_7.3.a024430.124","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01272.x"},{"key":"2018091410343384000_7.3.a024430.125","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113136660178"},{"key":"2018091410343384000_7.3.a024430.126","doi-asserted-by":"publisher","DOI":"10.2174\/1871526510909010015"},{"key":"2018091410343384000_7.3.a024430.127","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1983.04050080055010"},{"key":"2018091410343384000_7.3.a024430.128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.07.015"},{"key":"2018091410343384000_7.3.a024430.129","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl150"},{"key":"2018091410343384000_7.3.a024430.130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1440-1789.2009.01058.x","article-title":"Continuous intraventricular infusion of pentosan polysulfate: Clinical trial against prion diseases","volume":"29","year":"2009","journal-title":"Neuropathol"},{"key":"2018091410343384000_7.3.a024430.131","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11030-013-9477-3","article-title":"Prediction of antiprion activity of therapeutic agents with structure\u2013activity models","volume":"18","year":"2014","journal-title":"Mol Divers"},{"key":"2018091410343384000_7.3.a024430.132","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1114-9"},{"key":"2018091410343384000_7.3.a024430.133","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6664-6"},{"key":"2018091410343384000_7.3.a024430.134","doi-asserted-by":"publisher","DOI":"10.1038\/nature01457"},{"key":"2018091410343384000_7.3.a024430.135","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802759105"},{"key":"2018091410343384000_7.3.a024430.136","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-006-0772-y"},{"key":"2018091410343384000_7.3.a024430.137","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"2018091410343384000_7.3.a024430.138","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69835-8"},{"key":"2018091410343384000_7.3.a024430.139","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/1871526510909010092","article-title":"Therapeutic trials in human transmissible spongiform encephalopathies: Recent advances and problems to address","volume":"9","year":"2009","journal-title":"Infect Disord Drug Targets"}],"container-title":["Cold Spring Harbor Perspectives in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/cshperspect.a024430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T08:04:45Z","timestamp":1601193885000},"score":1,"resource":{"primary":{"URL":"http:\/\/perspectivesinmedicine.cshlp.org\/lookup\/doi\/10.1101\/cshperspect.a024430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":139,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,1]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1101\/cshperspect.a024430"],"URL":"https:\/\/doi.org\/10.1101\/cshperspect.a024430","relation":{},"ISSN":["2157-1422"],"issn-type":[{"value":"2157-1422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}